Methamphetamine Use and Schizophrenia: A Population-Based Cohort Study in California
- Russell C. Callaghan,
Ph.D. , - James K. Cunningham,
Ph.D. , - Peter Allebeck,
M.D., Ph.D. , - Tamara Arenovich,
M.Sc. , - Gautam Sajeev,
M.Sc. , - Gary Remington,
M.D., Ph.D. , - Isabelle Boileau,
Ph.D. , and - Stephen J. Kish,
Ph.D.
From the Centre for Addiction and Mental Health, Toronto; the Dalla Lana School of Public Health, the Departments of Psychiatry and Pharmacology, Faculty of Medicine, and the Institute of Medical Science, University of Toronto, Toronto; the Department of Family and Community Medicine, University of Arizona, Tucson; and the Department of Public Health Sciences, Karolinska Institutet, Stockholm.
From the Centre for Addiction and Mental Health, Toronto; the Dalla Lana School of Public Health, the Departments of Psychiatry and Pharmacology, Faculty of Medicine, and the Institute of Medical Science, University of Toronto, Toronto; the Department of Family and Community Medicine, University of Arizona, Tucson; and the Department of Public Health Sciences, Karolinska Institutet, Stockholm.
From the Centre for Addiction and Mental Health, Toronto; the Dalla Lana School of Public Health, the Departments of Psychiatry and Pharmacology, Faculty of Medicine, and the Institute of Medical Science, University of Toronto, Toronto; the Department of Family and Community Medicine, University of Arizona, Tucson; and the Department of Public Health Sciences, Karolinska Institutet, Stockholm.
From the Centre for Addiction and Mental Health, Toronto; the Dalla Lana School of Public Health, the Departments of Psychiatry and Pharmacology, Faculty of Medicine, and the Institute of Medical Science, University of Toronto, Toronto; the Department of Family and Community Medicine, University of Arizona, Tucson; and the Department of Public Health Sciences, Karolinska Institutet, Stockholm.
From the Centre for Addiction and Mental Health, Toronto; the Dalla Lana School of Public Health, the Departments of Psychiatry and Pharmacology, Faculty of Medicine, and the Institute of Medical Science, University of Toronto, Toronto; the Department of Family and Community Medicine, University of Arizona, Tucson; and the Department of Public Health Sciences, Karolinska Institutet, Stockholm.
From the Centre for Addiction and Mental Health, Toronto; the Dalla Lana School of Public Health, the Departments of Psychiatry and Pharmacology, Faculty of Medicine, and the Institute of Medical Science, University of Toronto, Toronto; the Department of Family and Community Medicine, University of Arizona, Tucson; and the Department of Public Health Sciences, Karolinska Institutet, Stockholm.
From the Centre for Addiction and Mental Health, Toronto; the Dalla Lana School of Public Health, the Departments of Psychiatry and Pharmacology, Faculty of Medicine, and the Institute of Medical Science, University of Toronto, Toronto; the Department of Family and Community Medicine, University of Arizona, Tucson; and the Department of Public Health Sciences, Karolinska Institutet, Stockholm.
From the Centre for Addiction and Mental Health, Toronto; the Dalla Lana School of Public Health, the Departments of Psychiatry and Pharmacology, Faculty of Medicine, and the Institute of Medical Science, University of Toronto, Toronto; the Department of Family and Community Medicine, University of Arizona, Tucson; and the Department of Public Health Sciences, Karolinska Institutet, Stockholm.
Supplemental Material
appi.ajp.2011.10070937_ds001.pdf (14 KB)